Cathie Wood Bets Big on a GLP-1 Stock Up 1,600% in 10 Years
ARK Invest's Cathie Wood is adding to a GLP-1 biotech position that has delivered massive decade-long gains.
If there's one investor who loves a high-conviction, moonshot bet, it's Cathie Wood. The ARK Invest founder has built her reputation on loading up on disruptive companies before the rest of Wall Street catches on — and her latest move puts her firmly inside the booming GLP-1 drug space, one of the hottest corners of healthcare investing right now.
GLP-1 drugs — the class behind blockbuster weight-loss and diabetes treatments you've probably heard about nonstop — have been reshaping the pharmaceutical landscape for years. What makes Wood's pick stand out is that it's not one of the household names dominating headlines. Instead, she's been accumulating shares in a company that has already surged roughly 1,600% over the past decade, a return that would have turned a modest $10,000 investment into around $170,000.
Read more SpaceX Stock vs. Dividend Stocks: What to Buy in July 2025 →
For everyday investors, it's worth understanding why Wood finds this corner of biotech compelling. GLP-1 therapies represent a massive, still-expanding market, and smaller players in the space can offer more upside than the giants — along with considerably more risk. Wood's ARK funds have historically leaned into that risk-reward trade-off, sometimes spectacularly right, sometimes painfully wrong.
The key takeaway here isn't just that a famous fund manager is buying a stock — it's that institutional attention on GLP-1 adjacent companies is intensifying. When a high-profile investor keeps adding to a position in a sector already on fire, it signals genuine long-term conviction, not just a short-term trade. Whether or not you follow Wood's lead, keeping an eye on the GLP-1 space feels like a reasonable idea for anyone thinking about healthcare allocations in their portfolio.
Continue reading at Yahoo Finance
